FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 880 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Paralyzed Bride Walks Down Aisle At Her Wedding & Surprises Groom November 20, 2021 Modest Effectiveness of Screening Colonoscopy for the Prevention of Colorectal Cancer... October 10, 2022 COVID Vaccine Basics for Cancer Patients January 18, 2021 England moves to a single-dose HPV vaccine June 21, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Tucatinib Loss of Y Chromosome in Men Makes Bladder Cancer More Aggressive What to Know About Peer-Reviewed Cancer Information and Its Role in... NHS England change of chief executive – what does it mean...
